Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Perspective Therapeutics (CATX) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Perspective Therapeutics (CATX) over the last 16 years, with Q3 2025 value amounting to $5.8 million.

  • Perspective Therapeutics' Change in Accured Expenses fell 6435.0% to $5.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$10.1 million, marking a year-over-year decrease of 16556.78%. This contributed to the annual value of $3.6 million for FY2024, which is 12886.2% up from last year.
  • Per Perspective Therapeutics' latest filing, its Change in Accured Expenses stood at $5.8 million for Q3 2025, which was down 6435.0% from -$2.0 million recorded in Q2 2025.
  • Perspective Therapeutics' Change in Accured Expenses' 5-year high stood at $16.2 million during Q3 2024, with a 5-year trough of -$11.3 million in Q4 2024.
  • For the 5-year period, Perspective Therapeutics' Change in Accured Expenses averaged around $419888.9, with its median value being $295000.0 (2022).
  • Its Change in Accured Expenses has fluctuated over the past 5 years, first surged by 372500.0% in 2022, then plummeted by 249682.88% in 2024.
  • Perspective Therapeutics' Change in Accured Expenses (Quarter) stood at -$1.5 million in 2021, then surged by 137.45% to $573000.0 in 2022, then dropped by 17.45% to $473000.0 in 2023, then crashed by 2496.83% to -$11.3 million in 2024, then skyrocketed by 150.99% to $5.8 million in 2025.
  • Its Change in Accured Expenses stands at $5.8 million for Q3 2025, versus -$2.0 million for Q2 2025 and -$2.6 million for Q1 2025.